Adding Aripiprazole (Abilify) to Sertraline and Ondansetron
Yes, it is safe to add aripiprazole to a regimen containing sertraline and ondansetron—the FDA label explicitly states no dosage adjustment is necessary when aripiprazole is coadministered with sertraline, and there are no clinically significant drug interactions between these medications 1.
Drug Interaction Profile
The combination is pharmacologically sound based on the following:
Sertraline + Aripiprazole: The FDA label specifically lists sertraline among drugs having "no clinically important interactions with ABILIFY" and confirms no dosage adjustment is necessary for either medication when used together 1.
Ondansetron considerations: While ondansetron is not specifically mentioned in the aripiprazole label, there are no known pharmacokinetic interactions. Both medications can prolong QT interval, so baseline ECG monitoring is prudent if the patient has cardiac risk factors, though this combination is commonly used in clinical practice.
No CYP450 concerns: Sertraline is not a strong CYP3A4 or CYP2D6 inhibitor, so standard aripiprazole dosing applies without adjustment 1.
Clinical Evidence for This Combination
The aripiprazole-sertraline combination has robust evidence supporting both efficacy and safety in major depressive disorder:
A randomized, double-blind trial of 412 patients showed the aripiprazole/sertraline combination was significantly more effective than sertraline alone (mean MADRS score change -9.2 vs -7.2, p=0.0070) 2.
Safety profile was excellent: Treatment-emergent adverse events were mostly mild-to-moderate, with akathisia (12.9%) being the most notable side effect. Discontinuation rates due to adverse events were very low (1.9% for combination vs 1.5% for sertraline alone) 2.
Even low-dose aripiprazole (2.5 mg/day) combined with sertraline 50 mg/day showed significant improvement in depressive symptoms as early as week 1, with no akathisia reported during the trial 3.
Practical Dosing Approach
Start with aripiprazole 2-5 mg/day and titrate based on response:
- Initial dose: 2-5 mg/day (lower doses minimize akathisia risk while maintaining efficacy) 3
- Target range: 3-12 mg/day for augmentation of antidepressants 2
- Titration: Increase gradually every 1-2 weeks based on tolerability
- Continue sertraline at current dose (no adjustment needed) 1
Key Monitoring Parameters
Monitor specifically for:
- Akathisia: Most common side effect (occurs in first 3 weeks in 76% of cases when it develops), usually mild-to-moderate severity 4. Younger patients (18-40 years) are at higher risk 4.
- Weight gain: Mean increase of 1.73 kg in clinical trials, though less than other atypical antipsychotics 4
- Sedation: Can be additive, particularly in the first few weeks 1
- Blood pressure: Monitor for orthostatic hypotension, especially during initiation 1
Important Caveats
QT prolongation: While not a contraindication, both ondansetron and aripiprazole can affect QT interval. Consider baseline ECG if the patient has cardiac disease, electrolyte abnormalities, or takes other QT-prolonging medications.
Metabolic effects: Aripiprazole has minimal propensity for metabolic disruption compared to other atypical antipsychotics, but baseline and periodic monitoring of weight, glucose, and lipids is appropriate 5.
Movement disorders: Unlike other antipsychotics, extrapyramidal symptoms beyond akathisia are uncommon with aripiprazole, but document baseline movement examination 1.
The combination is well-established, evidence-based, and safe when appropriately monitored, with the primary concern being manageable akathisia rather than serious drug interactions.